388 related articles for article (PubMed ID: 37322134)
21. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
24. Research progress on the immune microenvironment and immunotherapy in gastric cancer.
Mou P; Ge QH; Sheng R; Zhu TF; Liu Y; Ding K
Front Immunol; 2023; 14():1291117. PubMed ID: 38077373
[TBL] [Abstract][Full Text] [Related]
25. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
26. Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Subhash VV; Yeo MS; Tan WL; Yong WP
J Immunol Res; 2015; 2015():308574. PubMed ID: 26579545
[TBL] [Abstract][Full Text] [Related]
27. Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy.
Negura I; Pavel-Tanasa M; Danciu M
Cancer Treat Rev; 2023 Nov; 120():102629. PubMed ID: 37769435
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y; Tang F; Wei YQ; Wei XW
J Hematol Oncol; 2022 May; 15(1):61. PubMed ID: 35585567
[TBL] [Abstract][Full Text] [Related]
29. THE ROLE OF IMMUNOTHERAPY IN CANCER TREATMENT: CHECKPOINT INHIBITORS, CAR-T CELLS, AND VACCINES.
Arun J; Singh A; Shashidhar E; Patel G; Verma Y; Sapcota S
Georgian Med News; 2023 Jun; (339):105-112. PubMed ID: 37522784
[TBL] [Abstract][Full Text] [Related]
30. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for Gastric Cancer: Time for a Personalized Approach?
Dolcetti R; De Re V; Canzonieri V
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29844297
[TBL] [Abstract][Full Text] [Related]
32. Immune evasion mechanisms and therapeutic strategies in gastric cancer.
Ma ES; Wang ZX; Zhu MQ; Zhao J
World J Gastrointest Oncol; 2022 Jan; 14(1):216-229. PubMed ID: 35116112
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
34. [Progression of immunotherapy in gastric cancer].
Wei X; Xu R
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
[TBL] [Abstract][Full Text] [Related]
35. Emerging immunotherapy targets in lung cancer.
Zhu HH; Feng Y; Hu XS
Chin Med J (Engl); 2020 Oct; 133(20):2456-2465. PubMed ID: 32947361
[TBL] [Abstract][Full Text] [Related]
36. Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials.
Yadav D; Kwak M; Chauhan PS; Puranik N; Lee PCW; Jin JO
Semin Cancer Biol; 2022 Nov; 86(Pt 2):909-922. PubMed ID: 35181474
[TBL] [Abstract][Full Text] [Related]
37. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition.
Sundar R; Huang KK; Kumar V; Ramnarayanan K; Demircioglu D; Her Z; Ong X; Bin Adam Isa ZF; Xing M; Tan AL; Tai DWM; Choo SP; Zhai W; Lim JQ; Das Thakur M; Molinero L; Cha E; Fasso M; Niger M; Pietrantonio F; Lee J; Jeyasekharan AD; Qamra A; Patnala R; Fabritius A; De Simone M; Yeong J; Ng CCY; Rha SY; Narita Y; Muro K; Guo YA; Skanderup AJ; So JBY; Yong WP; Chen Q; Göke J; Tan P
Gut; 2022 Jul; 71(7):1277-1288. PubMed ID: 34433583
[TBL] [Abstract][Full Text] [Related]
39. CAR T‑cell therapy for gastric cancer: Potential and perspective (Review).
Long B; Qin L; Zhang B; Li Q; Wang L; Jiang X; Ye H; Zhang G; Yu Z; Jiao Z
Int J Oncol; 2020 Apr; 56(4):889-899. PubMed ID: 32319561
[TBL] [Abstract][Full Text] [Related]
40. Oxidative stress in the tumor microenvironment in gastric cancer and its potential role in immunotherapy.
Yu Y; Wu Y; Zhang Y; Lu M; Su X
FEBS Open Bio; 2023 Jul; 13(7):1238-1252. PubMed ID: 37171226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
